Opportunity Information: Apply for RFA CA 19 026
Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional) (RFA-CA-19-026) is a National Cancer Institute (NCI) funding opportunity that supports revision applications to existing, currently funded NCI P01 Program Project grants. The main idea is to let active P01 research teams add something substantially new to their already-approved work by bringing in a novel technology or instrument that was developed with support from NCI's Innovative Molecular Analysis Technologies (IMAT) program. Rather than funding an entirely new standalone project, this FOA is designed to strengthen and speed up the parent P01 by integrating an IMAT-derived approach that can expand the original research questions, improve the rigor or throughput of data collection and analysis, or otherwise accelerate the pace and impact of the ongoing program project.
A central goal of the announcement is independent validation of emerging IMAT technologies in real-world cancer research settings. In practice, that means the NCI is trying to bridge the gap between technology development and broad research adoption by paying for P01 teams to test, validate, and demonstrate the usefulness of these tools in ways that matter to the cancer research community. The FOA emphasizes accelerating the "suitability" of these technologies for appropriate research users, which typically implies demonstrating performance, reproducibility, usability, and relevance to important biological or clinical questions, not just showing that the technology works in a narrow or idealized setting.
The mechanism is a grant in the discretionary funding category, with the activity aligned to health (and tagged in the source data under education/health categories). It is explicitly a revision opportunity for P01 awards, meaning the applicant must already hold an eligible NCI P01 and is requesting additional support to incorporate the new IMAT-supported technology into the existing scope. The title includes "Clinical Trial Optional," indicating that the revision may include clinical trial elements if appropriate, but a clinical trial is not required for all applicants.
Funding is relatively targeted and modest compared with full P01 budgets: the listed award ceiling is $150,000, and the program expected to make about three awards. This size and number of awards reinforce the purpose of the FOA as an incentive and catalytic add-on, aimed at specific technology incorporation and validation activities rather than broad expansion of an entire research program. The announcement was created January 7, 2019, with an original closing date of September 27, 2019, reflecting a defined submission window typical of RFAs.
Eligibility is broad in terms of institution types, covering many domestic applicant categories including state, county, and local governments; special district governments; independent school districts; public and private institutions of higher education; federally recognized tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status (outside of higher education); for-profit organizations (other than small businesses); and small businesses, with an additional catch-all category referencing further eligibility details in the full announcement. Even with broad institutional eligibility on paper, the practical gating requirement is that the applicant must be a currently funded NCI P01 program project seeking a revision, since the FOA is not intended for new applicants without an active parent award.
Overall, this opportunity is best understood as a translation-and-adoption accelerator within NCI's IMAT ecosystem: it encourages interdisciplinary collaboration by pairing technology innovation (IMAT) with established cancer research programs (P01) to produce validated, usable tools and methods that can more quickly move from development into impactful cancer research applications.Apply for RFA CA 19 026
- The Department of Health and Human Services, National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394.
- This funding opportunity was created on Jan 07, 2019.
- Applicants must submit their applications by Sep 27, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $150,000.00 in funding.
- The number of recipients for this funding is limited to 3 candidate(s).
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is this funding opportunity?
Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional) (RFA-CA-19-026) is a National Cancer Institute (NCI) funding opportunity that supports revision applications to existing, currently funded NCI P01 Program Project grants. It is intended to help active P01 teams incorporate a substantially new technology or instrument that was developed with support from NCI's Innovative Molecular Analysis Technologies (IMAT) program.
Is this an opportunity for a brand-new (standalone) research project?
No. This announcement is specifically for revision applications to already-funded NCI P01 Program Project grants. The goal is to strengthen and accelerate the parent P01 by integrating an IMAT-supported approach, rather than creating an entirely new standalone project.
What is the main purpose of the revision?
The purpose is to add something substantially new to an already-approved P01 by bringing in a novel IMAT-derived technology or instrument. The revision is meant to expand the original research questions, improve the rigor or throughput of data collection and analysis, or otherwise accelerate the pace and impact of the ongoing program project.
What kinds of technologies are meant to be incorporated?
The FOA focuses on technologies or instruments developed with support from NCI's IMAT program. The intent is to integrate an IMAT-derived approach into an active P01 so it can be tested, validated, and demonstrated in real-world cancer research settings.
Why does the FOA emphasize "independent validation" of IMAT technologies?
A central goal is to validate emerging IMAT technologies independently in real cancer research environments. NCI is aiming to bridge the gap between technology development and broad adoption by supporting P01 teams as they test, validate, and demonstrate that these tools are useful in ways that matter to the cancer research community.
What does "accelerating the suitability" of IMAT technologies mean in practice?
Based on the FOA description, it generally implies demonstrating performance, reproducibility, usability, and relevance to important biological or clinical questions. The emphasis is on showing that the technology is ready for appropriate research users, not only that it can work under narrow or idealized conditions.
Who is eligible to apply?
Institutional eligibility categories listed include many domestic applicant types, such as state/county/local governments, special district governments, independent school districts, public and private institutions of higher education, federally recognized tribal governments and other tribal organizations, public housing authorities/Indian housing authorities, nonprofits (with and without 501(c)(3) status, outside of higher education), for-profit organizations (other than small businesses), and small businesses, along with a catch-all category referencing additional eligibility details in the full announcement.
Is there a practical eligibility requirement beyond institutional type?
Yes. Even though the institutional eligibility list is broad, the opportunity is explicitly a revision for P01 awards. The practical gating requirement is that the applicant must already hold an eligible, currently funded NCI P01 Program Project grant and be seeking additional support through a revision.
What grant mechanism and activity type does this use?
The opportunity uses a grant mechanism in a discretionary funding category, with the activity aligned to health (and tagged in the source data under education/health categories). It is a revision opportunity tied to the P01 Program Project structure.
Are clinical trials required?
No. The title includes "Clinical Trial Optional," which indicates that clinical trial elements may be included if appropriate, but a clinical trial is not required for all applicants.
How much funding is available per award?
The listed award ceiling is $150,000. The funding level is described as targeted and modest compared with full P01 budgets, reinforcing that the FOA is meant as a catalytic add-on for technology incorporation and validation activities.
How many awards does NCI expect to make?
The program expected to make about three awards.
What is the timeline for this opportunity?
The announcement was created on January 7, 2019, with an original closing date of September 27, 2019, reflecting a defined submission window typical of RFAs.
What types of work is this FOA trying to encourage within a P01?
It encourages interdisciplinary collaboration by pairing technology innovation (IMAT) with established cancer research programs (P01). The intended outcome is validated, usable tools and methods that can move more quickly from development into impactful cancer research applications.
What makes this opportunity different from expanding a whole program project?
The relatively small award ceiling ($150,000) and the limited number of expected awards (about three) signal that this FOA is designed as an incentive for specific technology incorporation and validation, rather than supporting a broad expansion of an entire research program.
What should applicants keep in mind about the relationship to the parent P01?
The revision is intended to integrate an IMAT-supported technology into the existing, currently funded P01 to strengthen and accelerate the approved work. The FOA frames this as adding substantially new capability that enhances the parent program project's impact and pace.
Browse more opportunities from the same category: Education, Health
Next opportunity: Strategic Prevention Framework – Partnerships for Success
Previous opportunity: Notice of Intent to Award
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 19 026
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 19 026) also looked into and applied for these:
| Funding Opportunity |
|---|
| Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional) Apply for RFA CA 19 023 Funding Number: RFA CA 19 023 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Revisions for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional) Apply for RFA CA 19 024 Funding Number: RFA CA 19 024 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Distance Learning and Telemedicine Grants. Apply for RUS 19 02 DLT Funding Number: RUS 19 02 DLT Agency: Department of Agriculture, Utilities Programs Category: Education, Health Funding Amount: $500,000 |
| Distance Learning and Telemedicine Grants--Opioid. Apply for RUS 19 01 DLT Funding Number: RUS 19 01 DLT Agency: Department of Agriculture, Utilities Programs Category: Education, Health Funding Amount: $500,000 |
| Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20 Clinical Trial Optional) Apply for RFA CA 19 034 Funding Number: RFA CA 19 034 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $800,000 |
| Optimizing the Management and Outcomes for Cancer Survivors Transitioning to Follow-up Care (R01 Clinical Trial Required) Apply for RFA CA 19 035 Funding Number: RFA CA 19 035 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| American Schools and Hospitals Abroad Program Worldwide Apply for 72ASHA19RFA00001 Funding Number: 72ASHA19RFA00001 Agency: Agency for International Development Category: Education, Health Funding Amount: $2,000,000 |
| Revision Applications to Support the Application of Informatics Technology for Cancer Research (R01 Clinical Trials Optional) Apply for RFA CA 19 062 Funding Number: RFA CA 19 062 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $100,000 |
| Revision Applications to Support the Application of Informatics Technology for Cancer Research (U01 Clinical Trials Optional) Apply for RFA CA 19 061 Funding Number: RFA CA 19 061 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $100,000 |
| Revision Applications to Support the Application of Informatics Technology for Cancer Research (U24 Clinical Trials Optional) Apply for RFA CA 19 063 Funding Number: RFA CA 19 063 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $100,000 |
| The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Required) Apply for RFA DA 20 024 Funding Number: RFA DA 20 024 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Limited Competition: Pediatric Brain Tumor Consortium (UM1 Clinical Trials Required) Apply for RFA CA 19 059 Funding Number: RFA CA 19 059 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $3,300,000 |
| Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Coordination, Analysis, and Scientific Outreach (UM1 Clinical Trial Not Allowed) Apply for RFA DA 20 027 Funding Number: RFA DA 20 027 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network (NCTN)(U24 Clinical Trial Not Allowed) Apply for RFA CA 20 002 Funding Number: RFA CA 20 002 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $3,000,000 |
| Communication and Decision Making for Individuals with Inherited Cancer Syndromes (U01 Clinical Trial Optional) Apply for RFA CA 20 006 Funding Number: RFA CA 20 006 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $600,000 |
| Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Clinical Trials Not Allowed) Apply for RFA CA 20 017 Funding Number: RFA CA 20 017 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trials Not Allowed) Apply for RFA CA 20 020 Funding Number: RFA CA 20 020 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Clinical Trials Not Allowed) Apply for RFA CA 20 019 Funding Number: RFA CA 20 019 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trials Not Allowed) Apply for RFA CA 20 018 Funding Number: RFA CA 20 018 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional) Apply for RFA CA 20 007 Funding Number: RFA CA 20 007 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 19 026", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.